ESMO Asia 2023
What’s On-Board
We're thrilled to announce that the highly-anticipated ESMO Asia Congress is returning again this year, and DelveInsight is proud to be part of it. Our team had the privilege of attending and showcasing our expertise at the ESMO Asia Congress 2023, leaving a lasting impression. This event presents a remarkable opportunity for the DelveInsight team to engage with global industry leaders. With over 25,000 members spanning 160 countries, ESMO serves as a hub for oncology professionals to explore current and future trends in the field.
Our experts will have the privilege of participating in insightful meetings, attending oncology workshops, and engaging in educational sessions that address key issues of significance to clinical oncologists and researchers. ESMO is a focal point for all stakeholders in the field, connecting cancer specialists with unparalleled knowledge and experience.
DelveInsight will be at the forefront of the latest developments presented at the ESMO Congress, including groundbreaking findings from cancer clinical trials and transformative drug studies. We are aligned with ESMO’s mission to break down international boundaries in cancer care, working together to advance oncology globally. Rest assured, we will integrate these discoveries and cutting-edge insights into our upcoming reports, providing our clients with invaluable insights into the future of oncology.
Don't miss your chance to connect with our experts at the ESMO Asia Congress 2023, taking place from December 1-3, 2023.
To join us, simply fill out the form provided. We look forward to connecting and collaborating with you at this prestigious event!
Oncology Conference Coverage Services
DelveInsight’s Oncology Conference Coverage Services provided a detailed analysis of conference coverage outcomes of various conferences, including ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, European CAR T-cell Meeting, IASLC 2023, leading to effective competitive intelligence assessment and anticipation of market trends to develop future road maps.
Oncology Portfolio Management
DelveInsight's Oncology Portfolio Management services are unrivaled in understanding skills in the cancer domain. Furthermore, we prioritize strategic goals, analyze developments in the oncology segment, understand the current needs of the oncology market, and seek to provide value for client services.
Rare Diseases Analysis
DelveInsight intends to provide useful reports that are relevant to the rare cancer market. Our analysts monitor competing products’ developmental, regulatory, and commercial milestones. It comprises features such as conference evaluation and company and R&D development evaluation to carry out the desired development of an oncological product for commercial purposes dealing with the client’s area of interest.
Consulting Services
Our multidimensional, purposeful, and credible consultancy services will aid in the acceleration of oncology product services, including aspects such as congress intelligence, conference coverage, CI asset/indication tracking, brand presence and penetration assessment, drug therapy uptake, and diagnostic landscape assessment to overcome several oncology market challenges.
Competitive Intelligence
We stand out from the crowd by hiring a specialized primary Competitive Intelligence research team. It constitutes analysts, senior analysts, and managers. Our CI force provides the finest opportunity and most accurate intelligence to be obtained and shared with our allies. Furthermore, extraordinary data collecting with the primary purpose of acquiring best-in-class intelligence and offering analysis in relation to our partners’ consulting goals.
R&D Analysis
Our research and development analyst understands the oncology domain to make value-based judgments and assist clients in achieving superior oncological R&D outcomes. The path of each oncological medicine through pre-clinical and clinical development is completed by evaluating the same factors as other candidates currently in the field. Similar is done for the oncology drugs as well. DelveInsight’s insightful oncological reports clarify uncertainties and challenge blind spots to provide the organization with timely intelligence.
Pipeline Assessment
DelveInsight's Oncological Pipeline Assessment promises a comprehensive picture of cancer therapies, clinical trials, and highlights of the cancer therapeutics landscape in a report format. Our Pipeline Assessment report type, which includes oncology-ready reports already available in our Report Store, gives insights across treatments, MoAs, Drugs, APIs, and Launch Insights of therapies in late-stage development to provide awareness of their launch timelines and strategies.
We welcome you to discuss your business-related concerns, and we can together find the best possible solution to help you proceed further in the oncological market.
The ESMO Asia 2023 conference and exhibition will take place at Suntec Singapore Convention & Exhibition Centre, Singapore, from 1-3 December 2023.